Potential role of sorafenib in the treatment of acute myeloid leukemia

Leuk Lymphoma. 2008 Dec;49(12):2246-55. doi: 10.1080/10428190802510349.


The identification of aberrant cellular pathways and dysfunctional molecules important in neoplastic transformation has begun to provide us with a number of targets for drug development. It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents. Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer. Its potential role in hematological malignancies, particularly acute myeloid leukemia (AML) is under evaluation. Here we describe the biological pathways in AML that are the potential targets of sorafenib action and discuss the early clinical data with the agent in solid tumors and AML.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Benzenesulfonates / pharmacology
  • Benzenesulfonates / therapeutic use*
  • Drug Delivery Systems
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Signal Transduction / drug effects
  • Sorafenib


  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib